Marie McDonnell, MD: New Basal Insulins for Type 2 Diabetes
Marie E. McDonnell, MD, of Brigham & Women's Hospital, Boston, Massachusetts, discusses implementing effective behavior change for patients with diabetes.
Perioperative major adverse cardiovascular and cerebrovascular events may be more common in patients with diabetes.
Investigators sought to determine an association between diabetes and HbA1C with postoperative outcomes.
Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after ...